Previous 10 | Next 10 |
LOTIS-2 updated results demonstrate durable responses of ZYNLONTA ™ with median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DLBCL LOTIS-3 updated Phase 1 data highlight potential of ZYNLONTA™ in combinat...
- Shareholders elect industry-leading financial executive Viviane Monges to Board of Directors ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and s...
Oral presentation of preliminary results from ongoing pivotal Phase 2 trial of camidanlumab tesirine in r/r Hodgkin lymphoma LOTIS trials evaluating ZYNLONTA™ as single agent and in combination with other therapies to also be highlighted ADC Therapeutics SA (N...
ZYNLONTA™ LOTIS-2 updated data includes median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DLBCL Subgroup analyses include patients with double- / triple-hit, advanced stage or transformed DLBCL, DLBCL refractory to fi...
ADC Therapeutics ([[ADCT]] +0.9%) announces that selling shareholders had agreed to a resale of 5.56M of the company's shares.The company highlighted that it will not receive any proceeds from the proposed offering.As of May 1, 2021, the company had a total of 76.73M outst...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will present at the Jefferies Vir...
Results of ADC Therapeutics' (ADCT) Phase 1 clinical trial of camidanlumab tesirine (Cami), an anti-CD25 ADC, in patients with relapsed or refractory Hodgkin and non-Hodgkin lymphomas have been published in The Lancet Haematology. The Phase 1 dose expansion trial enrolled 133 adult patients, ...
Camidanlumab tesirine (Cami) demonstrated anti-tumoral activity response rate in 86% of Hodgkin lymphoma patients at dose currently being evaluated in ongoing pivotal Phase 2 trial ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the developm...
ADC Therapeutics (ADCT) announces that Avid Bioservices, a contract development and manufacturing organization will serve as the commercial manufacturer for the humanized monoclonal antibody portion of Zynlonta (loncastuximab tesirine-lpyl).ADCT shares up 2.2% premarket tradin...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...